Brief: Sana Biotechnology Highlights Hypoimmune Allogeneic Car T Cell Programs And In Vivo Technology Platform

Sana Biotechnology

11/12/2022 23:01

Dec 11 (Reuters) - Sana Biotechnology Inc  SANA.O :
    * SANA BIOTECHNOLOGY HIGHLIGHTS HYPOIMMUNE ALLOGENEIC CAR T
CELL
PROGRAMS AND IN VIVO TECHNOLOGY PLATFORM WITH SIX PRESENTATIONS
AT 2022 ASH ANNUAL MEETING
    * SANA BIOTECH - TRANSPLANTED HYPOIMMUNE-MODIFIED ALLOGENEIC
CD19-TARGETED CAR T CELLS CONTROL TUMOR CELLS IN IMMUNOCOMPETENT
ALLOGENEIC HUMANIZED MICE
    * SANA BIOTECH - HIP-MODIFIED ALLOGENEIC BCMA-TARGETED CAR T
CELLS
DEMONSTRATE IN VITRO EFFICACY, CYTOKINE PRODUCTION AGAINST BCMA+
TARGET CELLS

Source text for Eikon:  ID:nGNX1kMMMr 
Further company coverage:  SANA.O 
 ((Reuters.Briefs@thomsonreuters.com;))